Literature DB >> 20650439

The effect of lipid and inflammatory profiles on the morphological changes of lipid-rich plaques in patients with non-ST-segment elevated acute coronary syndrome: follow-up study by optical coherence tomography and intravascular ultrasound.

Shigeho Takarada1, Toshio Imanishi, Kohei Ishibashi, Takashi Tanimoto, Kenichi Komukai, Yasushi Ino, Hironori Kitabata, Takashi Kubo, Atsushi Tanaka, Keizo Kimura, Masato Mizukoshi, Takashi Akasaka.   

Abstract

OBJECTIVES: The aim of this study was to determine the relationship between the morphological changes of nonculprit lipid-rich plaques and several clinical profiles in patients with non-ST-segment elevated acute coronary syndrome (NSTEACS).
BACKGROUND: Identification of coronary lesion with morphological characteristics of rupture-prone plaques is still difficult.
METHODS: Eighty-two consecutive patients with NSTEACS who underwent percutaneous coronary intervention were enrolled. The changes in total atheroma volume (TAV) of residual nonculprit lipid-rich plaques and the changes in the corresponding fibrous cap thickness (FCT) were assessed by intravascular ultrasound and optical coherence tomography, respectively, at baseline and after 9 months.
RESULTS: The percentage changes in TAV (mm(3)) of lipid-rich plaques and in the corresponding FCT (microm) over the 9-month follow-up period were 3.1 +/- 11% and 15 +/- 17%, respectively. There was no significant correlation between the changes in TAV and those in FCT. The change in TAV showed a significant correlation with reduction of the low-density lipoprotein/high-density lipoprotein (LDL/HDL) ratio (r = 0.42, p < 0.01). In contrast, the change in FCT showed no correlation with LDL/HDL ratio but had a significant positive correlation with changes in high-sensitivity C-reactive protein (r = 0.44, p < 0.01). Furthermore, in multivariate logistic analysis, statin use was an independent predictor of changes in well-stabilized plaques that showed both TAV reduction and FCT increase.
CONCLUSIONS: The changes in TAV and FCT of coronary plaques over a 9-month observation period were related to 2 different independent factors (i.e., reduction of LDL-cholesterol and high-sensitivity C-reactive protein, respectively). Furthermore, lipid-lowering therapy with statin has the potential to stabilize these parameters by both plaque reduction and FCT. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20650439     DOI: 10.1016/j.jcin.2010.05.001

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  12 in total

1.  Three-dimensional morphological response of lipid-rich coronary plaques to statin therapy: a serial optical coherence tomography study.

Authors:  Zhao Wang; Young-Seok Cho; Tsunenari Soeda; Yoshiyasu Minami; Lei Xing; Haibo Jia; Aaron Aguirre; Rocco Vergallo; Hang Lee; James G Fujimoto; Bo Yu; Ik-Kyung Jang
Journal:  Coron Artery Dis       Date:  2016-08       Impact factor: 1.439

2.  LDL Lowering After Acute Coronary Syndrome: Is Lower Better?

Authors:  Gautam Reddy; Vera Bittner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

3.  Lipid-lowering therapy stabilizes the complexity of non-culprit plaques in human coronary artery: a quantitative assessment using OCT bright spot algorithm.

Authors:  Yoshiyasu Minami; Taylor Hoyt; Jennifer E Phipps; Thomas E Milner; Lei Xing; Hang Lee; Bo Yu; Marc D Feldman; Ik-Kyung Jang
Journal:  Int J Cardiovasc Imaging       Date:  2016-12-16       Impact factor: 2.357

Review 4.  Imaging plaques to predict and better manage patients with acute coronary events.

Authors:  Hector M Garcia-Garcia; Ik-Kyung Jang; Patrick W Serruys; Jason C Kovacic; Jagat Narula; Zahi A Fayad
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

5.  [MINOCA-myocardial infarction with non-obstructive coronary arteries].

Authors:  C Hamm; C W Hamm
Journal:  Herz       Date:  2018-12       Impact factor: 1.443

6.  Optical coherence tomography imaging in acute coronary syndromes.

Authors:  Takashi Kubo; Yasushi Ino; Takashi Tanimoto; Hironori Kitabata; Atsushi Tanaka; Takashi Akasaka
Journal:  Cardiol Res Pract       Date:  2011-09-21       Impact factor: 1.866

7.  Impact of statins therapy on morphological changes in lipid-rich plaques stratified by 10-Year framingham risk score: A serial optical coherence tomography study.

Authors:  Yinchun Zhu; Lin Lin; Chao Wang; Haibo Jia; Sining Hu; Lulu Li; Xiling Zhang; Gonghui Zheng; Yan Wang; Rong Sun; Abigail Afolabi; Irina Mustafina; Jingbo Hou; Shaosong Zhang; Bo Yu
Journal:  Oncotarget       Date:  2017-04-18

8.  Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: An optical coherence tomography study.

Authors:  Yusuke Muramatsu; Yoshiyasu Minami; Ayami Kato; Aritomo Katsura; Toshimitsu Sato; Ryota Kakizaki; Teruyoshi Nemoto; Takuya Hashimoto; Kazuhiro Fujiyoshi; Kentaro Meguro; Takao Shimohama; Junya Ako
Journal:  Int J Cardiol Heart Vasc       Date:  2019-06-13

9.  Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension.

Authors:  Weon Kim; Myong Joo Hong; Jong Shin Woo; Won Yu Kang; Sun Ho Hwang; Wan Kim
Journal:  Chonnam Med J       Date:  2013-04-25

10.  Association between apolipoprotein B/A1 ratio and coronary plaque vulnerability in patients with atherosclerotic cardiovascular disease: an intravascular optical coherence tomography study.

Authors:  Fuxue Deng; Danni Li; Lei Lei; Qiang Yang; Qing Li; Hongtao Wang; Jie Deng; Qiangsun Zheng; Wei Jiang
Journal:  Cardiovasc Diabetol       Date:  2021-09-15       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.